Lofty valuations | Stretched balance sheets
Results and updates covered in our free update here include several companies carrying lofty valuations. The signs look encouraging, but even the mildest disappointment could see a sharp sell-off in their shares given the current ratings. Elsewhere, the balance sheet of another looks a little stretched to us. Read on here for this and other news from AIM.
Tristel: growth returns, but it’s still all about that FDA approval Tristel (AIM: TSTL), the highly-rated manufacturer of infection prevention products, announced its interim results for the six months to 31 December 2022. Tristel’s core business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand, and for the sporicidal disinfection of environmental surfaces under the Cache brand. It was a period which brought a resumption of the sort of growth we have become accustomed to from this business, with revenue climbing 16% to £17.5m. Of the increase…